Fecal Microbiota Transplantation for Irritable Bowel Syndrome Associated Food Intolerance

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorHelsinki University Central Hospital

About this trial

Previous studies have shown that stool transplantation (FMT) have positive effect in symptoms for some patients with irritable bowel syndrome (IBS). Studies have shown that it is possible by FMT to reverse the microbiome of the recipient's intestine in the direction of the microbiome of the donor. The effect on eating habits for engraftment of microbiome by FMT is unknown.

The purpose of this study is to investigate whether FMT relieves FODMAP diet extension without worsening intestinal symptoms in IBS patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults, age 18-75 years, knowledge of the Finnish language

IBS patients have been diagnosed with the Rome IV- criteria, all IBS-subtypes will be accepted to the trial

The patient must consume low FODMAP diet to control IBS symptoms

Patient must sign the informed consent

Disqualifiers

Diagnosed allergies to food components in the study dietary protocol

Pregnancy and breastfeeding

Antibiotic treatment less than three months prior enrolment

Faecal incontinence, i.e., inability to retain enema

Trial design

Design model

Single group

Treatments tested in this trial

  • FMT

    Biological/Vaccine

    FMT from healthy donor or placebo

Treatment groups

45 Participants
are divided into 2 treatment groups
Group A: FMT form healthy donorActive comparator 1 intervention
Group B: FMT plaseboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

The effect of FMT for tolerance of FODMAPs in the IBS patients' diet

With this study we aim to investigate if FMT treatment promotes inclusion and tolerance of FODMAPs in the IBS patients' diet.

Time frame
FMT and IBS

Secondary outcomes

1

Microbial components explaining the successful broadening of FODMAP diet in IBS patients.

We aim to investigate what are the microbial components explaining the successful broadening of their diet and identify microbial taxa engrafted from the donor explaining the dietary modifications.

Time frame
Microbiome and FODMAP
2

GI symptoms and bacterial fermentaiton status in IBS

Aim to investigate the gastrointestinal symptom change and see how changes in bacterial fermentation status (detected with hydrogen breath test) modulates the patients' symptoms and if this is related to the FMT treatment.

Time frame
Bacterial fermentation status and IBS

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Helsinki University Central Hospital

Lead sponsor

Turku University Hospital

Collaborator

University of Helsinki

Collaborator

Paijat-Hame Hospital District

Collaborator